OOIR: Observatory of International Research

Papers

(The H4-Index of npj Precision Oncology is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
KMT2C inactivation leads to PTEN downregulation and tolerance to DNA damage during cell cycle progression	336
MYSM1 promotes lung adenocarcinoma progression via TRAF2/3-mediated activation of MAPK and non-canonical NF-κB pathways	173
Sub-regional radiomics combining multichannel 2-dimensional or 3-dimensional deep learning for predicting neoadjuvant chemo-immunotherapy response in esophageal squamous cell carcinoma: a multicenter	141
Improved prediction of MAPKi response duration in melanoma patients using genomic data and machine learning	133
Multi-modal characterization of metabolic and immune gene clusters in adrenocortical carcinoma treatment	132
Development and testing of a polygenic risk score for breast cancer aggressiveness	126
Patient-level proteomic network prediction by explainable artificial intelligence	120
Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs	117
Tumor break load quantitates structural variant-associated genomic instability with biological and clinical relevance across cancers	111
Developing survival prediction models in colorectal cancer using epigenome-wide DNA methylation data from whole blood	92
Author Correction: An automated deep learning pipeline for EMVI classification and response prediction of rectal cancer using baseline MRI: a multi-centre study	80
Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study	74
Exosome- transported FER inhibitor suppresses progression of diffuse large B-cell lymphoma via regulating AJUBA/Hippo axis	73
Genome-wide analyses reveals an association between invasive urothelial carcinoma in the Shetland sheepdog and NIPAL1	70
Imaging and AI based chromatin biomarkers for diagnosis and therapy evaluation from liquid biopsies	69
The dynamic immune behavior of primary and metastatic ovarian carcinoma	63
Complement activation in tumor microenvironment after neoadjuvant therapy and its impact on pancreatic cancer outcomes	62
Grading of lung adenocarcinomas with simultaneous segmentation by artificial intelligence (GLASS-AI)	62
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP	62
Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials	62
BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study	61
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada	60
Interferon signaling and ferroptosis in tumor immunology and therapy	58
Constitutional mismatch repair deficiency mimicking Lynch syndrome is associated with hypomorphic mismatch repair gene variants	57
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates	56

A protein-encoding CCDC7 circular RNA inhibits the progression of prostate cancer by up-regulating FLRT3	56
Mucin-1: a promising pan-cancer therapeutic target	55
Artificial intelligence-driven prediction of lymph node metastasis in T1 esophageal squamous cell carcinoma using whole slide images	55
An automated deep learning pipeline for EMVI classification and response prediction of rectal cancer using baseline MRI: a multi-centre study	53
Barriers and opportunities in pancreatic cancer immunotherapy	51
Multiregional transcriptomic profiling provides improved prognostic insight in localized non-small cell lung cancer	49
Erigoster B targeting DECR1 induces ferroptosis of breast cancer cells via promoting phosphatidylcholine/arachidonic acid metabolism	49
Enhanced efficacy of ipilimumab plus nivolumab in angiogenic subtypes of metastatic clear-cell renal cell carcinoma	47
Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy	46
Collagen disorder architecture features are associated with clinical, molecular, genetic factors and survival outcomes in colon cancer	46
Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma	46
Single-cell landscape of bronchoalveolar immune cells in patients with immune checkpoint inhibitor-related pneumonitis	45
Prolonged response to dual immune checkpoint blockade in patients with advanced solid tumors: a case series	45
Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer	45
Machine learning model for predicting tertiary lymphoid structures and treatment response in triple-negative breast cancer	45
Discovery of prognostic lncRNAs in colorectal cancer using spatial transcriptomics	43
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab	43
ECM-based molecular subtypes define prognostic, EMT status, and therapeutic diversity in IDH-mutant gliomas	43